Ketamine: A Review of Clinical Pharmacokinetics and Pharmacodynamics in Anesthesia and Pain Therapy
Top Cited Papers
- 30 March 2016
- journal article
- review article
- Published by Springer Science and Business Media LLC in Clinical Pharmacokinetics
- Vol. 55 (9), 1059-1077
- https://doi.org/10.1007/s40262-016-0383-6
Abstract
Ketamine is a phencyclidine derivative, which functions primarily as an antagonist of the N-methyl-d-aspartate receptor. It has no affinity for gamma-aminobutyric acid receptors in the central nervous system. Ketamine shows a chiral structure consisting of two optical isomers. It undergoes oxidative metabolism, mainly to norketamine by cytochrome P450 (CYP) 3A and CYP2B6 enzymes. The use of S-ketamine is increasing worldwide, since the S(+)-enantiomer has been postulated to be a four times more potent anesthetic and analgesic than the R(−)-enantiomer and approximately two times more effective than the racemic mixture of ketamine. Because of extensive first-pass metabolism, oral bioavailability is poor and ketamine is vulnerable to pharmacokinetic drug interactions. Sublingual and nasal formulations of ketamine are being developed, and especially nasal administration produces rapid maximum plasma ketamine concentrations with relatively high bioavailability. Ketamine produces hemodynamically stable anesthesia via central sympathetic stimulation without affecting respiratory function. Animal studies have shown that ketamine has neuroprotective properties, and there is no evidence of elevated intracranial pressure after ketamine dosing in humans. Low-dose perioperative ketamine may reduce opioid consumption and chronic postsurgical pain after specific surgical procedures. However, long-term analgesic effects of ketamine in chronic pain patients have not been demonstrated. Besides analgesic properties, ketamine has rapid-acting antidepressant effects, which may be useful in treating therapy-resistant depressive patients. Well-known psychotomimetic and cognitive adverse effects restrict the clinical usefulness of ketamine, even though fewer psychomimetic adverse effects have been reported with S-ketamine in comparison with the racemate. Safety issues in long-term use are yet to be resolved.Keywords
This publication has 164 references indexed in Scilit:
- Repeated S-ketamine Infusions in Therapy Resistant Depression: A Case SeriesThe Journal of Clinical Pharmacology, 2013
- Non-opioid IV adjuvants in the perioperative period: Pharmacological and clinical aspects of ketamine and gabapentinoidsPharmacological Research, 2012
- Effect of Rifampicin on S-ketamine and S-norketamine Plasma Concentrations in Healthy Volunteers after Intravenous S-ketamine AdministrationAnesthesiology, 2011
- Exploring the pharmacokinetics of oral ketamine in children undergoing burns proceduresPediatric Anesthesia, 2011
- Taming the Ketamine TigerAnesthesiology, 2010
- Reduction of allodynia in patients with complex regional pain syndrome: A double-blind placebo-controlled trial of topical ketaminePain, 2009
- Ketamine Attenuates Neutrophil Activation After Cardiopulmonary BypassAnesthesia & Analgesia, 2002
- Update on the Neurophysiology of Pain Transmission and Modulation: Focus on the NMDA-ReceptorJournal of Pain and Symptom Management, 2000
- Ketamine Attenuates the Interleukin-6 Response After Cardiopulmonary BypassAnesthesia & Analgesia, 1998
- Pharmacodynamic modeling of the EEG effects of ketamine and its enantiomers in manJournal of Pharmacokinetics and Biopharmaceutics, 1987